We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+1.9%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$3.17M
AUM Growth
+$561K
Cap. Flow
+$147M
Cap. Flow %
4,647.33%
Top 10 Hldgs %
63.1%
Holding
323
New
68
Increased
74
Reduced
74
Closed
84

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$37.9M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$24.5M
3
MRK icon
Merck
MRK
+$12.3M
4
GILD icon
Gilead Sciences
GILD
+$11.7M
5
ACHN
Achillion Pharmaceuticals
ACHN
+$11.6M

Top Sells

Rank Stock Value
1
LRMR icon
Larimar Therapeutics
LRMR
+$4.64M
2
OCUL icon
Ocular Therapeutix
OCUL
+$3.33M
3
ACGN
Aceragen Inc
ACGN
+$2.48M
4
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
+$2.06M
5
PRQR icon
ProQR Therapeutics
PRQR
+$1.95M

Sector Composition

Rank Sector Weight
1 Healthcare 9.16%
2 Energy 0.42%
3 Industrials 0.14%
4 Consumer Staples 0.11%
5 Technology 0.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CASI
151
DELISTED
CASI Pharmaceuticals
CASI
$1.11K 0.04%
83,609
+4,760
+6% +$74.7K
ACHV icon
152
Achieve Life Sciences
ACHV
$613M
$1.06K 0.03%
210
-148
-41% -$723K
IMNN icon
153
Imunon
IMNN
$6.43M
$1.06K 0.03%
166
+126
+315% +$875K
AEGR
154
CALL
DELISTED
Aegerion Pharmaceuticals
AEGR
$1.05K 0.03%
+500
New +$12.6K
PSTV icon
155
Plus Therapeutics
PSTV
$24.8M
$1.02K 0.03%
1
– –
RXII
156
PUT
DELISTED
GALENA BIOPHARMA INC COM
RXII
$997 0.03%
6,600
-1,239
-16% -$187
CBAY
157
DELISTED
Cymabay Therapeutics
CBAY
$991 0.03%
100,800
-149,100
-60% -$1.2M
HTWR
158
PUT
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
$977 0.03%
+133
New +$10.1K
MDGN.WS
159
DELISTED
MEDGENICS INC WT PUR COM EXP 03/31/16
MDGN.WS
$922 0.03%
1,271,240
+429,528
+51% +$623K
IMNN icon
160
PUT
Imunon
IMNN
$6.43M
$907 0.03%
1
-2
-67% -$13.9K
NSPH
161
DELISTED
NANOSPHERE INC. COM NEW
NSPH
$872 0.03%
+111,254
New +$1.04M
MBLY
162
CALL
DELISTED
Mobileye N.V.
MBLY
$844 0.03%
+208
New +$9.76K
ESPR
163
CALL
DELISTED
Esperion Therapeutics
ESPR
$833 0.03%
+206
New +$6.31K
ALKS icon
164
Alkermes
ALKS
$8.23B
$810 0.03%
13,827
-25,868
-65% -$1.32M
TBRA
165
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
$788 0.02%
95,839
-16,555
-15% -$143K
CELG
166
PUT
DELISTED
Celgene Corp
CELG
$783 0.02%
70
-2,678
-97% -$282K
INCY icon
167
Incyte
INCY
$25.5B
$772 0.02%
+10,564
New +$690K
THC icon
168
CALL
Tenet Healthcare
THC
$22.5B
$760 0.02%
+150
New +$7.84K
HZNP
169
CALL
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$755 0.02%
586
-4,377
-88% -$54.8K
SSKN
170
DELISTED
Strata Skin Sciences
SSKN
$719 0.02%
11,985
+10,501
+708% +$861K
VNDA icon
171
CALL
Vanda Pharmaceuticals
VNDA
$303M
$716 0.02%
500
-2,816
-85% -$33.3K
NURO
172
DELISTED
NeuroMetrix, Inc. Common Stock
NURO
$708 0.02%
142
+20
+16% +$87.6K
A icon
173
PUT
Agilent Technologies
A
$39.8B
$700 0.02%
171
-2,154
-93% -$86.9K
SGEN
174
CALL
DELISTED
Seagen Inc. Common Stock
SGEN
$678 0.02%
211
– –
GEVO icon
175
Gevo
GEVO
$358M
$601 0.02%
313
-428
-58% -$883K
5 6
7
8 9

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q4 2014 Portfolio in Review

As of Q4 2014, Sabby Management held 323 positions worth $3.17M, up 22% from $2.6M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Sabby Management deployed $147M of net new capital in Q4 2014, opening 68 new positions and adding to 74 existing holdings. Its largest new stake was Pfizer: 1,322,658 shares worth $39.1K.

By sector, the portfolio is most concentrated in Healthcare at 9.2% of assets, up from 6.3% a quarter earlier, followed by Energy and Industrials.

On the sell side, the largest reduction was Larimar Therapeutics, an estimated $4.64M trimmed.

  • Sabby Management's largest Q4 2014 buy was Pfizer: 1,322,658 shares worth $39.1K.
  • Sabby Management added most to Achillion Pharmaceuticals in Q4 2014, an estimated $11.6M increase.
  • Sabby Management's biggest Q4 2014 reduction was Larimar Therapeutics, cutting an estimated $4.64M.
  • Sabby Management fully exited Aceragen Inc in Q4 2014, selling an estimated $2.48M.
  • Sabby Management's ten largest holdings make up 63% of its $3.17M portfolio in Q4 2014.
  • Sabby Management opened 68 new positions and closed 84 in Q4 2014.
  • Sabby Management's portfolio value rose 22% quarter-over-quarter to $3.17M.

Based on Sabby Management's 13F filing for Q4 2014, filed 17 Feb 2015.